ATE462447T1 - Verfahren und mittels zur manipulierung der expression des uncoupling proteins - Google Patents

Verfahren und mittels zur manipulierung der expression des uncoupling proteins

Info

Publication number
ATE462447T1
ATE462447T1 AT00943076T AT00943076T ATE462447T1 AT E462447 T1 ATE462447 T1 AT E462447T1 AT 00943076 T AT00943076 T AT 00943076T AT 00943076 T AT00943076 T AT 00943076T AT E462447 T1 ATE462447 T1 AT E462447T1
Authority
AT
Austria
Prior art keywords
protein expression
expressed
uncoupling protein
ucp
manipulating
Prior art date
Application number
AT00943076T
Other languages
English (en)
Inventor
Martha Newell
Original Assignee
Univ Vermont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vermont filed Critical Univ Vermont
Application granted granted Critical
Publication of ATE462447T1 publication Critical patent/ATE462447T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
AT00943076T 1999-06-23 2000-06-22 Verfahren und mittels zur manipulierung der expression des uncoupling proteins ATE462447T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14057499P 1999-06-23 1999-06-23
PCT/US2000/017245 WO2000078941A2 (en) 1999-06-23 2000-06-22 Methods and products for manipulating uncoupling protein expression

Publications (1)

Publication Number Publication Date
ATE462447T1 true ATE462447T1 (de) 2010-04-15

Family

ID=22491870

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00943076T ATE462447T1 (de) 1999-06-23 2000-06-22 Verfahren und mittels zur manipulierung der expression des uncoupling proteins

Country Status (9)

Country Link
US (2) US7816319B2 (de)
EP (1) EP1194168B1 (de)
JP (1) JP2003503319A (de)
AT (1) ATE462447T1 (de)
AU (1) AU780815B2 (de)
CA (1) CA2375508A1 (de)
DE (1) DE60044087D1 (de)
HK (1) HK1047032A1 (de)
WO (1) WO2000078941A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381413B1 (en) 1998-04-17 2008-06-03 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
EP1194168B1 (de) 1999-06-23 2010-03-31 University Of Vermont And State Agricultural College Verfahren und mittels zur manipulierung der expression des uncoupling proteins
GB9930100D0 (en) * 1999-12-17 2000-02-09 Smithkline Beecham Plc New use
WO2004111199A2 (en) 2003-06-12 2004-12-23 University Of Colorado System Technology Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
US7510710B2 (en) 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
CN104997783A (zh) 2005-03-25 2015-10-28 Alt解决方案公司 端粒酶阳性细胞中端粒长度的调节和癌症治疗
NZ562234A (en) 2005-04-26 2009-09-25 Pfizer P-cadherin antibodies
EP1877060A2 (de) * 2005-04-28 2008-01-16 The Regents of the University of Colorado Systeme und verfahren zur behandlung menschlicher entzündungskrankheiten und proliferativer erkrankungen mit einer für die hemmung des fettsäurestoffwechsels und der glykolyse sorgenden verbindung
JP2008543734A (ja) * 2005-05-02 2008-12-04 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド 脂肪酸代謝および解糖の阻害を提供する化合物の組み合わせ、または二官能性化合物を用いるヒトの炎症性および増殖性疾患を処置するためのシステムおよび方法
US8609623B2 (en) 2005-05-18 2013-12-17 Alt Solutions Inc. Pharmacological modulation of telomere length in cancer cells for prevention and treatment of cancer
US20070032383A1 (en) * 2005-07-27 2007-02-08 Newell M K Systems, methods, and compositions for modifying the metabolism of plants and of euucaryotic microbes
GB0610317D0 (en) * 2006-05-24 2006-07-05 Medical Res Council Antiparasitic compounds and compositions
US8367633B2 (en) * 2007-08-06 2013-02-05 University Of Rochester Methods of treating B-cell cancers
US8394377B2 (en) * 2008-02-21 2013-03-12 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
US9073985B2 (en) 2008-07-14 2015-07-07 The Regents Of The University Of Colorado, A Body Corporate Methods and products for treating proliferative diseases
WO2010051347A1 (en) * 2008-10-31 2010-05-06 David Sheikh-Hamad A method for cardioprotection
US8450090B2 (en) 2009-10-06 2013-05-28 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for promoting fatty acid production in plants
SG181703A1 (en) * 2009-12-18 2012-07-30 Harvard College Beta-cell replication promoting compounds and methods of their use
US9938279B2 (en) * 2013-04-09 2018-04-10 Energenesis Biomedical Co., Ltd Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935450A (en) * 1982-09-17 1990-06-19 Therapeutical Systems Corporation Cancer therapy system for effecting oncolysis of malignant neoplasms
US4724234A (en) * 1982-09-17 1988-02-09 Therapeutical Systems Corp. Method for producing oncolysis
US5585363A (en) * 1987-05-05 1996-12-17 City Of Hope Circumvention of human tumor drug resistance
US6113946A (en) * 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
CA2164641A1 (en) * 1993-06-07 1994-12-22 Dinah S. Singer Use of an mhc class i suppressor drug for the treatment of autoimmune diseases and transplantation rejection
CA2260766A1 (en) 1996-07-12 1998-01-22 Emory University Regulation of apoptosis and in vitro model for studies thereof
WO1998031396A1 (en) * 1997-01-15 1998-07-23 Duke University Respiration uncoupling protein
WO1998045313A1 (en) * 1997-04-04 1998-10-15 Amylin Pharmaceuticals, Inc. Novel uncoupling protein and methods of use
AU7466198A (en) * 1997-04-09 1998-10-30 Beth Israel Deaconess Medical Center Ucp3: an uncoupling protein homologue
EP1077724A2 (de) 1998-04-17 2001-02-28 The University Of Vermont Verfahren und produkte die mit metabolischen interaktionen in krankheiten zusammenhangen
US7381413B1 (en) * 1998-04-17 2008-06-03 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
JP2002536009A (ja) 1999-02-09 2002-10-29 レキシコン・ジェネティクス・インコーポレーテッド ヒト脱共役タンパク質およびそれをコードするポリヌクレオチド
EP1194168B1 (de) 1999-06-23 2010-03-31 University Of Vermont And State Agricultural College Verfahren und mittels zur manipulierung der expression des uncoupling proteins
US7105718B2 (en) * 2000-03-31 2006-09-12 The Regents Of The University Of Colorado Compositions and methods for regulating metabolism in plants
EP1578983A3 (de) 2001-10-12 2005-12-07 The Regents of the University of Colorado Verfahren zur regulation der expression costimulierender moleküle mit reaktivem sauerstoff
US7341559B2 (en) * 2002-09-14 2008-03-11 Masimo Corporation Pulse oximetry ear sensor

Also Published As

Publication number Publication date
JP2003503319A (ja) 2003-01-28
US7816319B2 (en) 2010-10-19
AU780815B2 (en) 2005-04-21
DE60044087D1 (de) 2010-05-12
AU5760000A (en) 2001-01-09
WO2000078941A3 (en) 2001-02-22
US20110206755A1 (en) 2011-08-25
WO2000078941A2 (en) 2000-12-28
EP1194168B1 (de) 2010-03-31
HK1047032A1 (zh) 2003-02-07
CA2375508A1 (en) 2000-12-28
US20060247199A1 (en) 2006-11-02
EP1194168A2 (de) 2002-04-10

Similar Documents

Publication Publication Date Title
DE60044087D1 (de) Verfahren und mittels zur manipulierung der expression des uncoupling proteins
PL1685243T3 (pl) Unieśmiertelnione ptasie linie komórkowe do wytwarzania wirusów
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
ATE469219T1 (de) Zusammensetzungen, methoden und reagentien zur nukleinsäureisolierung mittels oberflächenaktiven substanzen und proteasen
WO2006127809A3 (en) Methods for expansion and analysis of cultured hematopoietic stem cells
DE69739996D1 (de) Methoden und Zusammensetzungen zur Herstellung von Polypeptiden
AU6380001A (en) Porous ferro- or ferrimagnetic glass particles for isolating molecules
DK15182A (da) Fremgangsmaade til fremstilling af recombinant-dna
ATE430807T1 (de) Verfahren zur kultivierung von circovirus
ATE278010T1 (de) Methode um proteine aus einem einzeller zu extrahieren
ATE466080T1 (de) Formulierungen und verfahren zum denaturieren von proteinen
WO2002002783A3 (en) Expression vectors
ATE472334T1 (de) Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind
DK1272669T3 (da) High-throughput screening af udtrykte DNA-biblioteker i trådsvampe
DE60111783D1 (de) Verfahren zur herstellung und reinigung von sekretierten proteinen und herstellung von protein-arrays
ATE268810T1 (de) Methode zur zellyse
ATE313068T1 (de) Thromboplastin-reagenzien und verfahren zur herstellung und anwendung derselben
DE69928395D1 (de) Cyclin-e2 proteine und dafür kodierende gene
PT935652E (pt) Produtos de factor de crescimento de queratinocitos-2
ATE299944T1 (de) System zur herstellung von proteinen
WO1999047673A3 (en) Isolated mammalian membrane protein genes and related reagents
WO2004078915A3 (en) Cell culture
DE60326494D1 (de) Mannosyl(1-2)glycosyl(1-2)glycerat zur stabilisierung und konservierung von biomaterialien
ATE402261T1 (de) Partikel zur gentherapie
WO2004094989A3 (en) Methods of host cell protein analysis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties